Corcept Therapeutics Incorporated (CORT) shares fell 50.50%, trading at $34.74, down $35.45, after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration regarding its relacorilant application.
The sharp sell-off followed news that the FDA did not approve relacorilant for its intended indication and outlined additional requirements before potential future approval, prompting investor concern about the drug's regulatory path and commercial prospects.
On the day of the announcement, CORT opened near $70.00, dropped to an intraday low of $33.80, and saw a high near $71.25, compared with a previous close of $70.19. The stock trades on the Nasdaq.
Trading volume was coming in well above the stock's average daily volume, reflecting significant market reaction to the regulatory setback.
Corcept's 52-week range is approximately $39.50 - $103.25, underscoring volatility tied to clinical and regulatory developments.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.